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IDENTIFICATION OF FETAL DNA AND CELLS IN SKIN LESIONS FROM WOMEN
WITH SYSTEMIC SCLEROSIS
CAROL M. ARTLETT, PH.D., J. BRUCE SMITH, M.D.,

ABSTRACT
Background Systemic sclerosis is a disease of unknown origin which often occurs in women after
their childbearing years. It has many clinical and histopathological similarities to chronic graft-versushost disease. Recent studies indicate that fetal stem
cells can survive in the maternal circulation for many
years post partum. This finding suggests that fetal
cells persisting in the maternal circulation or tissues
could be involved in the pathogenesis of systemic
sclerosis by initiating a graft-versus-host reaction.
Methods We used the polymerase chain reaction
(PCR) to identify Y-chromosome sequences in DNA
extracted from peripheral-blood cells and skin lesions from women with systemic sclerosis of recent
onset. To confirm the PCR findings, we used fluorescence in situ hybridization of peripheral-blood cells
and cells within chronic inflammatory-cell infiltrates
in biopsy specimens of affected skin.
Results Y-chromosome sequences were found in
DNA from peripheral-blood cells in 32 of 69 women
with systemic sclerosis (46 percent), as compared
with 1 of 25 normal women (4 percent, P0.001),
and in T lymphocytes from 3 women with systemic
sclerosis who had male offspring. Furthermore,
Y-chromosome sequences were identified in skinbiopsy specimens from 11 of 19 women with systemic sclerosis (58 percent); 9 of the 11 were known
to have carried male fetuses. Nucleated cells containing Y chromosomes were detected by fluorescence in situ hybridization in paraffin-embedded sections of skin lesions from all seven women we tested
whose skin-biopsy specimens contained Y-chromosome sequences.
Conclusions Fetal antimaternal graft-versus-host
reactions may be involved in the pathogenesis of
systemic sclerosis in some women. (N Engl J Med
1998;338:1186-91.)
©1998, Massachusetts Medical Society.

S

YSTEMIC sclerosis is a connective-tissue disease of unknown origin that is characterized
by cutaneous and visceral fibrosis; production
of autoantibodies, including anticentromere
and anti-topoisomerase antibodies; and prominent
microvascular changes, with endothelial-cell damage
and proliferation of subendothelial connective tissue. The highest incidence of systemic sclerosis occurs between 45 and 55 years of age,1,2 and it is three
to eight times as frequent in women as in men.3-5
These observations suggest that pregnancy-related
events are involved in its pathogenesis, although epidemiologic studies to evaluate to what extent a pre1186 
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vious pregnancy is a risk factor for systemic sclerosis
have not been performed.
Systemic sclerosis has clinical features similar to
those of graft-versus-host disease,6 and it has therefore been postulated that it may be a form of that disease.7-11 Skin, lung, and esophageal involvement is
prominent in both diseases,9,10,12 and both are characterized by lymphocytic infiltration of affected tissues,13-15 up-regulation of inflammatory cytokines,16-18
and fibrosis of the dermis and visceral organs.19 Furthermore, in a recent study, the systemic sclerosis–
specific autoantibodies Scl-70 and Pm-Scl were found
in 6 of 19 patients (32 percent) with chronic graftversus-host disease who presented with clinical symptoms and findings similar to those of diffuse systemic
sclerosis.20 Graft-versus-host disease due to the transplacental transfer of maternal T cells has been reported in infants,21 and erythema toxicum neonatorum has been postulated to be a mild, self-limited
form of graft-versus-host disease caused by maternal
cells in newborns.22
During pregnancy, fetal and maternal cells of various types are transferred between the mother and
the fetus, predominantly from the fetus to the mother.23 Fetal erythrocytes and leukocytes can be found
in the peripheral blood of up to 25 percent of pregnant women during the first trimester24 and 40 to
70 percent of women by the third trimester.25 Fetal
stem cells engrafted in the maternal lymphoid organs or bone marrow may help to maintain tolerance to the semiallogeneic fetoplacental graft, and
fetal hematopoietic stem cells have been detected in
the circulation of women up to 27 years post partum.26 It has been suggested that a microchimerism
established by fetal cells together with activation of
such cells may induce a chronic graft-versus-host
disease manifesting as systemic sclerosis.27-29
To test this hypothesis, it was first necessary to
demonstrate the presence of fetal nucleated cells in
affected tissues from women with systemic sclerosis
who had previously been pregnant. For this purpose,
we examined the male-specific Y-chromosome sequence DYZ1 as a marker for fetal cells in affected
tissues from women with systemic sclerosis. We de-
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scribe the presence of the Y-chromosome–specific
sequence in DNA extracted from the peripheral
blood and affected skin of women with systemic
sclerosis. These observations provide support for the
hypothesis that a fetal antimaternal graft-versus-host
reaction may be an immunopathogenic mechanism
in the development of systemic sclerosis in some
women.

Sequence Analysis of the PCR-Amplified Product
The 148-bp PCR product was sequenced to confirm its identity. The fragment was cloned into the TA cloning vector (Clontech, Palo Alto, Calif.) and sequenced with M13 forward and
reverse primers. The sequence results were analyzed with the program GenBank Search.
Fluorescence in Situ Hybridization
of Peripheral-Blood Cells

We extracted DNA from peripheral-blood cells of 69 women
with systemic sclerosis and 25 normal women by a procedure
involving sodium chloride–ethanol precipitation.30 Two of the
women with systemic sclerosis had had male children, but the
pregnancy histories of the remainder of these women and of
the 25 normal women were not known. DNA was also extracted
from biopsy specimens of active skin lesions from 19 women who
had had systemic sclerosis for 18 months or less, and from peripheral-blood cells of 2 of these women. Sixteen of the 19 women with
systemic sclerosis had been pregnant before the onset of disease.
As controls, DNA was extracted from skin-biopsy specimens of
7 women with osteoarthritis and 61 female relatives of these
7 women (who were subjects of another study), 29 percent of
whom were known to have had male children and 15 percent of
whom were known to have had female children (31 percent were
nulliparous, but the pregnancy histories of the remainder were
not known). We also extracted DNA from biopsy specimens of
skin and fascia from active lesions of nine women with eosinophilia myalgia syndrome and two women with eosinophilic fasciitis
and from a muscle-biopsy specimen from one woman with polymyositis. One of these 12 women had had multiple pregnancies;
the histories of the remainder were not known.
The diagnosis of systemic sclerosis was established according to
the criteria of the American College of Rheumatology (previously
known as the American Rheumatism Association).31 All the women attended the Scleroderma Center of Thomas Jefferson University Hospital between 1987 and 1997. The mean age of the women with systemic sclerosis was 53 years (range, 20 to 86), and the
mean age of the normal subjects and control patients was 49 years
(range, 25 to 75). The study protocol was approved by the institutional review board of Thomas Jefferson University, and informed consent was obtained from all subjects.

Peripheral-blood cells from three women with systemic sclerosis who had carried male fetuses, one woman with systemic sclerosis who had never been pregnant, and two normal women were
separated by a magnetic cell-separation device (Immunicon,
Huntington Valley, Pa.). Peripheral-blood mononuclear cells were
isolated by Ficoll–Hypaque centrifugation (Pharmacia Biotech,
Piscataway, N.J.) and washed twice in phosphate-buffered saline
containing 0.1 percent bovine serum albumin. The cells were resuspended in 0.85 ml of solution, and 20 ml (0.25 mg per milliliter) of mouse monoclonal antibodies directed either against
CD3 (T cells) or against CD14 (monocytes) and CD45 (leukocytes) was added. The reaction mixtures were incubated at room
temperature for 25 minutes, and 0.85 ml of a freshly prepared
1:20 dilution of goat antimouse antibodies conjugated to magnetic colloidal particles (Immunicon) was added. After a further
10 minutes of incubation, the cells were washed in 10 ml of phosphate-buffered saline, centrifuged, and resuspended in 1.7 ml of
phosphate-buffered saline.
The resuspended cells were transferred to a collection vessel
and inserted into a magnetic field for 15 minutes at room temperature. A new collection vessel containing 1.7 ml of phosphatebuffered saline was then raised onto the collecting loops, and the
cells were recovered by agitating the collection device for one to
two minutes. Cells recovered from the wire loops and those not
adhering to the loops were suspended in 50 ml of fresh 3:1 methanol–acetic acid solution for fixation. Between 30 and 40 ml of
the cell suspension was then pipetted onto clean glass slides and
air-dried. The number of cells on each slide was approximately
5000 per square centimeter. The X- and Y-chromosome probes
were pipetted onto the slides and incubated as described below
for the tissue sections. Signals were visualized with a Leitz Orthoplan II fluorescence microscope with a triple-bandpass filter
(Leitz, Rockleigh, N.J.). In each subject, 3000 nuclei were examined, and the number of signals for each probe was recorded. Image capture and recording were performed with the Oncor Image
Analysis System (Oncor, Gaithersburg, Md.).

Polymerase-Chain-Reaction Analysis
for Y-Chromosome–Positive Cells

Fluorescence in Situ Hybridization
of Paraffin-Embedded Skin-Biopsy Specimens

A specific Y-chromosome sequence was detected by amplifying
DNA in a nested polymerase chain reaction (PCR) with primers
Y1-1 and Y1-2, as described previously.32 The first amplification
was done with primers Y1-1 and Y1-2, and the second amplification was done with primers designed by our laboratory; they were
Y1-3, which has the sequence 5CAGGCCTGTCCATTACACTACA3, and Y1-4, which has the sequence 5GAATGGGAACGAATGGAGTGAA3. Sixty amplification cycles were performed in
the presence of 10 percent dimethyl sulfoxide and 10 U of
Taq polymerase (Perkin–Elmer Cetus, Foster City, Calif.) in a
Rapidcycler PCR thermocycler (Idaho Technologies, Idaho Falls,
Idaho). The conditions for amplification were denaturation at
94°C (five seconds), annealing at 60°C (two seconds), and extension at 72°C (five seconds) for 20 cycles, followed by 40 cycles of
denaturation at 94°C (five seconds), annealing at 54°C (two seconds), and extension at 72°C (five seconds). All PCR analyses
contained a blank (without DNA) for a negative control and a
known positive sample for the Y sequence (male DNA). The resulting 148-bp Y-chromosome–specific fragment was identified
by ethidium bromide staining after electrophoresis on a 1.5 percent agarose gel.

Sections were cut from paraffin-embedded skin-biopsy specimens from seven women with systemic sclerosis in whom PCR
amplification of DNA extracted from skin lesions yielded the
148-bp fragment. The sections were analyzed for the presence of
Y-chromosome–positive cells by fluorescence in situ hybridization. Skin-biopsy specimens from 10 women without systemic
sclerosis were examined simultaneously. The sections were deparaffinized in xylene for 10 minutes and washed twice for 5 minutes
each in 100 percent ethanol. The sections were treated with 0.1
percent pronase at 45°C for 10 minutes and then with 0.25 mg
of proteinase K per milliliter at 45°C for 30 minutes, after which
they were dehydrated in 70, 80, and 95 percent ethanol for
1 minute each. The X- and Y-chromosome probes (Oncor) were
diluted 1:10 with Hybrisol VI (Oncor), and 10 ml was pipetted
onto each section and covered with plastic film. The slides were
heated at 70°C for five minutes, incubated overnight at 37°C,
washed at 70°C in 2 saline sodium citrate (1 saline sodium
citrate is 0.15 M sodium chloride and 0.015 M sodium citrate)
for five minutes, counterstained with 0.1 mg of 4,6-diamidino2-phenylindole in an antifade solution (Oncor), and viewed with
an epi-fluorescence microscope (Zeiss, Thornwood, N.Y.) with a
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triple-bandpass filter. The nuclei in the paraffin-embedded skinbiopsy specimens were examined by fluorescence in situ hybridization for both the X chromosome (fluorescein) and the Y chromosome (Texas red). The results from the control and test groups
were compared by the chi-square test with Yates’ correction.
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RESULTS
PCR Analyses of Peripheral-Blood and Skin DNA

The Y-chromosome sequence was amplified from
DNA extracted from peripheral-blood cells in 32 of
the 69 women with systemic sclerosis (46 percent),
but in only 1 of the 25 normal women (4 percent,
P0.001). Cloning and sequencing confirmed the
identity of the Y-chromosome–specific product amplified from the DNA samples of the women with
systemic sclerosis. The amplified product had 98
percent sequence identity with the DYZ1 sequence
unique to the Y chromosome, indicating that it
was a male-chromosome sequence and not an unrelated gene.
Y-chromosome–specific DNA was detected in
skin lesions of 11 of the 19 women in whom it was
sought (58 percent), but in none of the skin-biopsy
specimens of the 68 women with osteoarthritis or
their relatives (P0.001). The results of a representative experiment are shown in Figure 1. A prominent band represents the 148-bp product amplified
from Y-chromosome DNA in samples from three
women with systemic sclerosis (lanes 5, 8, and 10;
arrow) and a similar product in DNA from skinbiopsy specimens from two normal men (lanes 3 and
9). The faster-migrating band seen in all lanes represents primer–dimer formation. The sample obtained from Patient 4 (lane 8) had such a high concentration of male DNA that the PCR results are
those expected for a male pattern. No Y-chromosome–specific sequence material was detected in the
DNA extracted from the active lesions of the women
with the eosinophilia myalgia syndrome, eosinophilic fasciitis, or polymyositis.
Fluorescence in Situ Hybridization
of Peripheral-Blood Cells

Cell populations enriched either for CD3 T cells
or for CD14 and CD45 cells from three women
with systemic sclerosis who had carried male fetuses
(Patients 1, 18, and 23) contained Y-chromosome
sequences (Table 1 and Fig. 2). No Y-chromosome–
positive cells were detected in cell populations from
these women that were depleted of CD14 and
CD45 cells or CD3 cells, nor in any of the cells from
the two normal women or a woman with systemic
sclerosis who had never been pregnant (Patient 17).
Fluorescence in Situ Hybridization
of Skin-Biopsy Specimens

Nucleated cells containing Y chromosomes were
detected in the skin-biopsy specimens of all seven
women with systemic sclerosis whose specimens con1188 

Figure 1. PCR Analysis of DYZ1 in DNA Extracted from Active
Skin Lesions in Women with Systemic Sclerosis.
Lane 1 shows a 100-bp size marker; lane 2 is blank; lane 3
shows DNA from a normal man; lane 4 shows DNA from Patient 5; lane 5 shows DNA from Patient 14; lane 6 shows DNA
from Patient 15; lane 7 shows DNA from Patient 16; lane 8
shows DNA from Patient 4; lane 9 shows DNA from a normal
man; and lane 10 shows DNA from Patient 2. The samples in
lanes 3, 5, 8, 9, and 10 show a band corresponding to the 148bp product amplified from Y-chromosome DNA, as indicated
by the arrow. The faster-migrating band in all lanes represents
primer–dimer formation, as illustrated by its presence in lane
2, which contains no DNA (blank).

tained Y-chromosome sequences as detected by
PCR and whose skin-biopsy specimens were tested
by in situ hybridization. The majority of the Y-chromosome–containing nucleated cells were present
within inflammatory-cell infiltrates localized in the
extracellular matrix of the deep dermis (Fig. 3A) or
in the walls of small vessels (Fig. 3B). Y-chromosome–containing nucleated cells were not seen in
any of the skin biopsy specimens from the 10 normal women studied.
Pregnancy History

Among the 11 women with systemic sclerosis
whose skin-biopsy specimens contained Y-chromosome–specific sequences detected by PCR amplification, all but 2 were known to have carried male fetuses (Table 2). Among the eight women with
systemic sclerosis who had negative PCR skin-biopsy
results, three (Patients 17, 19, and 20) had never
been pregnant and had systemic sclerosis before the
age of 20 years, one (Patient 21) had delivered two
girls, and one (Patient 22) had delivered one girl.
The remaining three women had died or were lost
to follow-up. Of the 68 women with osteoarthritis
or their relatives whose skin-biopsy specimens were
examined, 30 percent were known to have had male
offspring.
DISCUSSION

The results described here demonstrate the presence of fetal nucleated cells in the skin lesions of
women with systemic sclerosis and thus support the
hypothesis that persistent fetal cells in the maternal
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TABLE 1. RESULTS OF FLUORESCENCE IN SITU HYBRIDIZATION OF MAGNETICALLY SORTED CELLS
FROM PERIPHERAL BLOOD OF TWO NORMAL SUBJECTS AND FOUR PATIENTS WITH SYSTEMIC SCLEROSIS.
SUBJECTS

PREGNANCY HISTORY*

Normal subjects‡
Subject 1
G0, P0
Subject 2
G0, P0
Patients with systemic
sclerosis
Patient 1§
G2, P2 (both M)
Patient 17¶
G0, P0
Patient 18
G3, P3 (2 M, 1 F)
Patient 23**
G1, P0 (M)

NO.

OF

Y-CHROMOSOME–CONTAINING CELLS
CD14

CD14-

3000 CELLS†

CD3-DEPLETED

ND
ND

ND
ND

0
0

0
0

2
0
2
2

0
0
0
0

2
0
2
3

0
0
0
0

AND

CD45

PER

CD3

AND

CD45-DEPLETED

*G denotes number of pregnancies, P pregnancies carried to term, M male, and F female.
†CD3 denotes T cells, CD14 monocytes, CD45 leukocytes (these also contain CD3 cells), and ND not done.
‡These were normal women who had never been pregnant and whose age was similar to that of the women with systemic sclerosis.
§Patient 1 was a 36-year-old woman who had a very rapid and progressive onset of systemic sclerosis within one year
after the delivery of her second son.
¶Patient 17 was a 15-year-old girl who had never been pregnant; her age at the onset of systemic sclerosis was 15 years.
Patient 18 was a 41-year-old woman with two sons in whom systemic sclerosis was diagnosed during her third pregnancy, which was with a female fetus.
**Patient 23 was a 39-year-old woman who had miscarried a male fetus.

Figure 2. Fluorescence in Situ Hybridization of CD3 Cells from the Peripheral Blood of a Woman with Systemic Sclerosis.
The X chromosome was labeled with Texas red (red signal), and the Y chromosome with fluorescein (green signal). The nuclei are
stained blue by 4,6-diamidino-2-phenylindole in an antifade solution (0.1 mg per milliliter) and viewed with an epi-fluorescence
microscope with a triple-bandpass filter. The arrow indicates a nucleus containing both X and Y chromosomes, and the arrowhead
indicates a nucleus with only an X chromosome. (2000.)
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TABLE 2. PREGNANCY HISTORY AND ONSET OF SYSTEMIC
SCLEROSIS IN WOMEN POSITIVE FOR Y CHROMOSOMES IN DNA
EXTRACTED FROM BIOPSY SPECIMENS OF AFFECTED SKIN.*

PATIENT
NO.

PREGNANCY
HISTORY

1
2
3
4

G2, P2
G4, P4
G2, P2
G5, P4

5

G3, P2

6
7

G3, P3
G5, P3

8
9

G1, P1
G2, P1

A

10
11

G3, P1
Unknown

SEX AND YEAR OF BIRTH OF CHILDREN,
MISCARRIAGE, OR TERMINATION
OF PREGNANCY

M 1987; M 1990
M 1956; M 1957; M 1959; F 1962
F 1964; M 1967
F 1955; F 1956; M 1958; M 1966;
first-trimester miscarriage, sex
unknown, 1968
F 1980; F 1981; termination at
3 mo, sex unknown, 1983
F 1956; M 1960; F 1963
F 1956; miscarriage at 3 mo, sex
unknown, 1957; F 1958; miscarriage at 5 mo, M, 1960; F 1963
M 1956
Termination at 2 mo, sex unknown,
1988; M 1995
M 1965; F 1967; F 1970
Unknown

ONSET OF
DISEASE†

1991
1991
1991
1991

1990
1991
1977

1989
1989
1989
1990

*G denotes number of pregnancies, P pregnancies carried to term,
M male, and F female.
†Onset of disease was determined by the appearance of clinically detectable cutaneous changes of systemic sclerosis.

B
Figure 3. Fluorescence in Situ Hybridization of a ParaffinEmbedded Tissue Section from an Active Skin Lesion in a
Woman with Systemic Sclerosis.
The X chromosome was labeled with fluorescein (green signal), and the Y chromosome with Texas red (red signal). The
sections were counterstained with 4,6-diamidino-2-phenylindole in an antifade solution (0.1 mg per milliliter) and viewed
with an epi-fluorescence microscope with a triple-bandpass filter. The nuclei are stained blue. In Panel A (1200), a nucleus
with a Y signal (red) is seen deep within the dermis (arrow). A
nucleus containing two X signals (green) is identified by an
arrowhead. In Panel B (1200), a nucleus containing both
X (green) and Y (red) signals is shown within the wall of a vessel (arrow). A nucleus containing two X chromosomes (green
signals) is identified by an arrowhead.

circulation or tissues mediate a graft-versus-host reaction, resulting in autoimmune disease.27-29
The fate of the cells transferred from the fetal to
the maternal circulation (or vice versa) is not known,
although transferred stem cells would be expected to
mature either to relatively short-lived B cells or to
longer-lived T cells. Thus, it is likely that the fetal
cells in the skin lesions of women with systemic sclerosis are T cells. Although activated T cells have profound effects on fibroblast proliferation and biosyn1190 

thetic activity, there is no evidence that the foreign
cells detected in the affected tissues of patients with
systemic sclerosis are capable of stimulating the biosynthesis of connective tissue by resident fibroblasts.
It is likely that the hosts were immunologically
unaware of the fetal cells, because the cells were not
eliminated immunologically, as would have been expected. This tolerance of the fetal cells by the host
may be due to maternal–fetal HLA compatibility.33
Tissues from women with the eosinophilia myalgia
syndrome, eosinophilic fasciitis, or polymyositis did
not contain Y-chromosome sequences; presumably,
these women either had no male offspring or, if
they did, fetal cells did not become localized in their
tissues.
Passage of cells from the fetus to the mother is a
frequent and expected occurrence, and passage of
cells from the mother to the fetus also occurs.22,34
Our study offers no explanation for the occurrence
of systemic sclerosis in women who have not had
children or in men. Maternal cells do reach the fetus,34 and if they persisted they could cause systemic
sclerosis in women who have not had children or in
men. Persistence of allogeneic T cells after blood
transfusion may also explain the occurrence of systemic sclerosis in men or in nulliparous women.35,36
Our results indicate that the fetal cells that cross
the placenta during pregnancy either remain in the
circulation or migrate to various tissue sites. We hy-
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pothesize that a subsequent event, such as an environmental exposure (viral, chemical, or other), activates them, initiating a cascade of events that results
in systemic sclerosis.
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